Book Lynch Syndrome IHC Test | Lahalak Medical Platform

An advanced screening to detect genetic predisposition to colorectal and endometrial cancers by analyzing DNA repair proteins, facilitating family prevention and personalized treatment planning for optimal medical outcomes.

Scientific name: Immunohistochemistry (IHC) for MMR Proteins (Lynch Syndrome)

An advanced laboratory test performed on tumor tissue to evaluate MMR proteins. It helps diagnose hereditary Lynch syndrome and determines patient suitability for modern immunotherapy treatments and future prevention strategies.

Immunohistochemistry (IHC) for MMR Proteins (Lynch Syndrome) - Lynch Syndrome Early Screening

Service type Histopathology laboratory test

Duration 3-5 working days

Fasting Fasting is not required

Included Services

Immunohistochemical staining analysis
Detailed pathology report
Result interpretation guidance

Medical Service Information

Purpose of the Procedure

Identify patients with hereditary Lynch syndrome.
Assess the risk of developing future secondary cancers.
Assist family members in initiating early preventive screenings.
Guide oncologists in selecting the most effective immunotherapy.

Who Should Get Tested

Patients diagnosed with colorectal cancer.
Patients diagnosed with endometrial cancer.
Individuals with a strong family history of early-onset cancers.

Clinical Significance

Normal Result: Indicates presence of MMR proteins and low risk of Lynch syndrome.
Abnormal Result: Indicates loss of protein expression, requiring further genetic testing.